FDA-cleared profile

Opulus™ Lymphoma Precision

Roche Molecular Systems, Inc. · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.

Clinical role
Segmentation, visualization, and volumetric measurement support
Images and patients
PET/SPECT/Nuclear Medicine · Whole-body FDG-PET/CT
Key limitation
Keep in mind: The device is assistive for already diagnosed FDG-avid lymphoma, is not a screening tool or diagnostic substitute, and requires trained physician review and final interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole-body FDG-PET/CT Input: Whole-body FDG-PET/CT in standard DICOM format, consisting of PET with associated attenuation-correction CT, from patients with pathologically diagnosed FDG-avid lymphoma.
  • Who uses it?Intended users: Trained interpreting physicians, including radiologists and nuclear medicine physicians
  • What does the software produce?Output: Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.
  • What is its most important limitation?Key limitation: The device is assistive for already diagnosed FDG-avid lymphoma, is not a screening tool or diagnostic substitute, and requires trained physician review and final interpretation.

Clinical takeaway. Clinical role: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.

Evidence takeaway. Evidence from the reviewed source record: Test-set validation used 182 unique patients across multiple geographies and PET/CT vendors; the FDA compares cube-root-transformed total metabolic tumor volume differences in centimeters, using a 2.5 cm threshold on that transformed scale, against a reference generated by nine radiologists and nuclear medicine physicians.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Segmentation, visualization, and volumetric measurement support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Whole-body FDG-PET/CT in standard DICOM format, consisting of PET with associated attenuation-correction CT, from patients with pathologically diagnosed FDG-avid lymphoma.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult lymphoma imaging and treatment-response assessment for patients already diagnosed with FDG-avid lymphoma
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Trained interpreting physicians, including radiologists and nuclear medicine physicians
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The device is assistive for already diagnosed FDG-avid lymphoma, is not a screening tool or diagnostic substitute, and requires trained physician review and final interpretation.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Test-set validation used 182 unique patients across multiple geographies and PET/CT vendors; the FDA compares cube-root-transformed total metabolic tumor volume differences in centimeters, using a 2.5 cm threshold on that transformed scale, against a reference generated by nine radiologists and nuclear medicine physicians.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Test-set validation used 182 unique patients across multiple geographies and PET/CT vendors; the FDA compares cube-root-transformed total metabolic tumor volume differences in centimeters, using a 2.5 cm threshold on that transformed scale, against a reference generated by nine radiologists and nuclear medicine physicians.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Cube-root-transformed TMTV mean difference below 2.5 cm

-0.2 cm on cube-root-transformed TMTV scale

  • EndpointAlgorithm minus reference cube-root-transformed total metabolic tumor volume for the below-2.5-cm transformed-TMTV group
  • PopulationTest-set FDG-PET/CT validation
  • Tested versionOpulus Lymphoma Precision submitted in K243863; build not stated

Cube-root-transformed TMTV mean difference at or above 2.5 cm

-0.23 cm on cube-root-transformed TMTV scale

  • EndpointAlgorithm minus reference cube-root-transformed total metabolic tumor volume for the at-or-above-2.5-cm transformed-TMTV group
  • PopulationTest-set FDG-PET/CT validation
  • Tested versionOpulus Lymphoma Precision submitted in K243863; build not stated

Mean segmentation Dice

0.7 Dice

  • EndpointLesion segmentation overlap
  • PopulationIndependent FDG-PET/CT validation
  • Tested versionOpulus Lymphoma Precision submitted in K243863; build not stated

Opulus Lymphoma Precision TMTV and segmentation validation

  • DesignRetrospective test-set validation against pooled physician reference
  • Population182 unique patients from multiple geographies and GE, Siemens, and Philips PET/CT systems
  • Scopeexact submission
  • Tested versionOpulus Lymphoma Precision submitted in K243863; build not stated
  • Samplen=182
  • IndependenceIndependence not established

K243863

The FDA describes the test data as independent from training data; reference pool comprised nine radiologists and nuclear medicine physicians. Independence of investigators or sponsorship was not established. TMTV differences are on the cube-root-transformed scale, with the 2.5 cm group threshold on that scale.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Whole-body FDG-PET/CT in standard DICOM format, consisting of PET with associated attenuation-correction CT, from patients with pathologically diagnosed FDG-avid lymphoma.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K243863: Opulus Lymphoma Precision

  2. Routing

    Source context, not route validation: The submission describes standard DICOM PET/CT input, report generation, and image/segmentation-mask overlays; current PACS/workstation routing and deployment architecture were not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K243863: Opulus Lymphoma Precision

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources establish DICOM image-processing function and commercial distribution, but not a current hosting model or regional data flow.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 ·

  4. Returned objects

    Source context, not route validation: Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K243863: Opulus Lymphoma Precision

  5. Viewer/worklist/report

    Unresolved route: Localization and segmentation of FDG-avid lesions, overlay visualization, segmentation masks, a total metabolic tumor volume measurement, and a report/image overlay; the physician may accept or reject the algorithm output but cannot modify it.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K243863: Opulus Lymphoma Precision

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The submission describes standard DICOM PET/CT input, report generation, and image/segmentation-mask overlays; current PACS/workstation routing and deployment architecture were not established.
  • Exact FDA submission
  • Checked 2026-09-06

DICOM PET/CT image-processing workflow

AccessGUDID lists Opulus Lymphoma Precision as a DICOM image-processing software device and records it as in commercial distribution; the current hosting model and local integration are not documented there.

exact submission · checked 2026-09-07

DICOM overlay and report output

The exact submission describes DICOM PET/CT input with report, lesion overlay, and segmentation-mask output for physician review.

exact submission · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243863
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
PET/SPECT/Nuclear Medicine
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Whole-body FDG-PET/CT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, government device registry, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Opulus Lymphoma Precision Roche reimbursement"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. The Roche page read describes a lab-assay reimbursement portal and does not name this product. This records what was found, not that none exists.

  • Deployment: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed sources establish DICOM image-processing function and commercial distribution, but not a current hosting model or regional data flow.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    No scoped current security, data-flow, access-control, retention, or incident-response documentation was established.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K243863: Opulus Lymphoma Precision

    U.S. Food and Drug Administration - Published 2025-05-30 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Opulus™ Lymphoma Precision model card (K243863)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AccessGUDID: Opulus Lymphoma Precision (07613336231098)

    U.S. National Library of Medicine - Accessed 2026-09-07

    Scope: exactProductIdentity, commercialDistributionStatus, deviceType, implementationCapabilities

  8. Roche lymphoma focus area

    Roche - Accessed 2026-09-07

    Scope: vendorWideLymphomaContext

Research history

  1. K243863 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251528

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2025-07-03
FDA-cleared K232000

syngo.via MI Workflows; Scenium; syngo MBF

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.via MI Workflows VB80A, Scenium VE60, and syngo MBF VB30 support PET, SPECT, nuclear-medicine, CT, and MR viewing, quantification, analysis, longitudinal comparison, organ segmentation, tumor-burden assessment, tau analysis, myocardial blood-flow analysis, and selected radiotherapy-planning support.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-11-28
FDA-cleared K232712

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-10-03
FDA-cleared K231572

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation in oncology, cardiology, neurology, inflammation, infection, and other disorders. The CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-07-26

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history